Navigation Links
Endologix Comments on Alleged Patent Infringement
Date:10/8/2009

IRVINE, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, acknowledged today that it has become aware that Cook Medical has filed a lawsuit against Endologix in the United States District Court alleging that Endologix infringes two of Cook's U.S. patents.

John McDermott, Endologix President and Chief Executive Officer, said, "We have just become aware of the lawsuit filed by Cook alleging that Endologix infringes two of Cook's patents, one of which was granted in 1991 and the other in 1998. The patent granted in 1991 expires next week. Together with our patent counsel, we are conducting a thorough evaluation and will provide more information as soon as available."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the alleged claims of infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                        INVESTOR CONTACTS:
    Endologix, Inc.                         The Ruth Group
    John McDermott, CEO                     Nick Laudico (646) 536-7030
    (949) 595-7200                          Zack Kubow (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
2. ACRO Comments on NEJM Article on Globalization of Clinical Research
3. Arpida Comments on FDAs Anti-infective Drugs Advisory Committee Outcome
4. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. Arpida Provides Further Comments on the Pivotal Phase III Trials
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
9. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
10. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
11. United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 Puerto Rico ... Puerto Rico Healthcare and Life Sciences Report 2016 ... page Puerto Rico Healthcare and Life Sciences Report 2016 ... into the fifth largest territory in the world for pharma ... device and diagnostics manufacturing, and more universities per square mile ...
(Date:2/10/2016)... , Feb. 10, 2016 Convergence ... confluence of various technologies that results in ... unavailable. These opportunities create a cyclical system ... turn, drives the development of new technologies. ... characterized by technology convergences, which are constantly ...
(Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... 2016 , ... Pediatric therapists are challenged to use evidence ... the Goal Attainment Scale (GAS) captures 20% more change in outcomes than other ... the Goal Attainment Scale, Education Resources Inc. is offering a course focused on ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine ... provide a solution that ensures the integrity of biological samples while operating at ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans ... start of Medicare Part D a decade ago, according to The Senior Citizens ... adults on how they are coping with rapidly rising costs. “The implications are ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian Injury is ... may be one of many possible sources: sports, car accidents, falls, work accidents, ... Mastering Rehab Solutions for the Complexities of Concussions is designed for ...
Breaking Medicine News(10 mins):